Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.
It has an incubation period of 14-180 days.
Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.
Dr Rajneesh Kumar, a senior consultant at the Department of Gastroenterology and Hepatology, Singapore General Hospital, highlights the high prevalence of hepatitis, and speaks to Roshini Claire Anthony about the transmission, prevention, and treatment of the disease.
Reducing the wait time for the hepatitis C virus (HCV) rapid antibody point-of-care test, from 20 minutes to 5 minutes, does not affect its sensitivity and is just as good for ruling out infection, according to a study.
Achieving the World Health Organization’s (WHO) target to eliminate hepatitis C virus (HCV) by 2030 is possible in Singapore, but this requires immediate scaling up of treatment among injectable drug users (IDUs) together with harm reduction efforts, as suggested in a study.
Use of direct-acting antivirals to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.
Diabetic patients with hepatitis C virus (HCV) may benefit from direct-acting antiviral agents, with a significant portion of patients having a clinically significant reduction in glycated haemoglobin (HbA1c), suggests a recent study. This effect has been sustained among responders over 1.5 years of follow-up.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.